Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation
Caveolin-1 (Cav1) is the main protein component of the membrane lipid rafts caveolae. Cav1 serves as a scaffolding protein that compartmentalizes a multitude of signaling molecules and sequesters them in their inactive state. Due to its function in the negative regulation of signal transduction, los...
Uložené v:
| Vydané v: | American journal of translational research Ročník 5; číslo 1; s. 80 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.01.2013
|
| Predmet: | |
| ISSN: | 1943-8141, 1943-8141 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Caveolin-1 (Cav1) is the main protein component of the membrane lipid rafts caveolae. Cav1 serves as a scaffolding protein that compartmentalizes a multitude of signaling molecules and sequesters them in their inactive state. Due to its function in the negative regulation of signal transduction, loss of Cav1 has been implicated in the pathogenesis of many cancers, but its role in cutaneous squamous cell carcinoma (cSCC) is largely unexplored. cSCC is a multi-stage disease characterized by the development of benign, premalignant lesions and their progression into malignant cancer. Here, we use a two-stage carcinogenesis protocol to elucidate the function of Cav1 in the different stages of benign papilloma development: initiation and promotion. First, we demonstrate that Cav1 knock-out (KO) mice are more susceptible to benign papilloma development after being subjected to a DMBA/TPA initiation/promotion protocol. Treatment of wild-type (WT) and Cav1 KO mice with DMBA alone shows that both groups have similar rates of apoptosis. In contrast, treatment of these groups with TPA alone indicates that Cav1 KO mice are more susceptible to promoter treatment as evidenced by increased epidermal proliferation. Furthermore, primary keratinocytes isolated from Cav1 KO mice have a proliferative advantage over WT keratinocytes in both low- and high-calcium medium, conditions that promote proliferation and induce differentiation, respectively. Collectively, these data indicate that Cav1 functions to suppress proliferation in the epidermis, and loss of this function promotes the development of benign skin tumors. |
|---|---|
| AbstractList | Caveolin-1 (Cav1) is the main protein component of the membrane lipid rafts caveolae. Cav1 serves as a scaffolding protein that compartmentalizes a multitude of signaling molecules and sequesters them in their inactive state. Due to its function in the negative regulation of signal transduction, loss of Cav1 has been implicated in the pathogenesis of many cancers, but its role in cutaneous squamous cell carcinoma (cSCC) is largely unexplored. cSCC is a multi-stage disease characterized by the development of benign, premalignant lesions and their progression into malignant cancer. Here, we use a two-stage carcinogenesis protocol to elucidate the function of Cav1 in the different stages of benign papilloma development: initiation and promotion. First, we demonstrate that Cav1 knock-out (KO) mice are more susceptible to benign papilloma development after being subjected to a DMBA/TPA initiation/promotion protocol. Treatment of wild-type (WT) and Cav1 KO mice with DMBA alone shows that both groups have similar rates of apoptosis. In contrast, treatment of these groups with TPA alone indicates that Cav1 KO mice are more susceptible to promoter treatment as evidenced by increased epidermal proliferation. Furthermore, primary keratinocytes isolated from Cav1 KO mice have a proliferative advantage over WT keratinocytes in both low- and high-calcium medium, conditions that promote proliferation and induce differentiation, respectively. Collectively, these data indicate that Cav1 functions to suppress proliferation in the epidermis, and loss of this function promotes the development of benign skin tumors.Caveolin-1 (Cav1) is the main protein component of the membrane lipid rafts caveolae. Cav1 serves as a scaffolding protein that compartmentalizes a multitude of signaling molecules and sequesters them in their inactive state. Due to its function in the negative regulation of signal transduction, loss of Cav1 has been implicated in the pathogenesis of many cancers, but its role in cutaneous squamous cell carcinoma (cSCC) is largely unexplored. cSCC is a multi-stage disease characterized by the development of benign, premalignant lesions and their progression into malignant cancer. Here, we use a two-stage carcinogenesis protocol to elucidate the function of Cav1 in the different stages of benign papilloma development: initiation and promotion. First, we demonstrate that Cav1 knock-out (KO) mice are more susceptible to benign papilloma development after being subjected to a DMBA/TPA initiation/promotion protocol. Treatment of wild-type (WT) and Cav1 KO mice with DMBA alone shows that both groups have similar rates of apoptosis. In contrast, treatment of these groups with TPA alone indicates that Cav1 KO mice are more susceptible to promoter treatment as evidenced by increased epidermal proliferation. Furthermore, primary keratinocytes isolated from Cav1 KO mice have a proliferative advantage over WT keratinocytes in both low- and high-calcium medium, conditions that promote proliferation and induce differentiation, respectively. Collectively, these data indicate that Cav1 functions to suppress proliferation in the epidermis, and loss of this function promotes the development of benign skin tumors. Caveolin-1 (Cav1) is the main protein component of the membrane lipid rafts caveolae. Cav1 serves as a scaffolding protein that compartmentalizes a multitude of signaling molecules and sequesters them in their inactive state. Due to its function in the negative regulation of signal transduction, loss of Cav1 has been implicated in the pathogenesis of many cancers, but its role in cutaneous squamous cell carcinoma (cSCC) is largely unexplored. cSCC is a multi-stage disease characterized by the development of benign, premalignant lesions and their progression into malignant cancer. Here, we use a two-stage carcinogenesis protocol to elucidate the function of Cav1 in the different stages of benign papilloma development: initiation and promotion. First, we demonstrate that Cav1 knock-out (KO) mice are more susceptible to benign papilloma development after being subjected to a DMBA/TPA initiation/promotion protocol. Treatment of wild-type (WT) and Cav1 KO mice with DMBA alone shows that both groups have similar rates of apoptosis. In contrast, treatment of these groups with TPA alone indicates that Cav1 KO mice are more susceptible to promoter treatment as evidenced by increased epidermal proliferation. Furthermore, primary keratinocytes isolated from Cav1 KO mice have a proliferative advantage over WT keratinocytes in both low- and high-calcium medium, conditions that promote proliferation and induce differentiation, respectively. Collectively, these data indicate that Cav1 functions to suppress proliferation in the epidermis, and loss of this function promotes the development of benign skin tumors. |
| Author | Capozza, Franco Lisanti, Michael P Sotgia, Federica Trimmer, Casey |
| Author_xml | – sequence: 1 givenname: Casey surname: Trimmer fullname: Trimmer, Casey organization: Department of Cancer Biology/Stem Cell Biology and Regenerative Medicine, Thomas Jefferson University Philadelphia, PA, USA – sequence: 2 givenname: Federica surname: Sotgia fullname: Sotgia, Federica – sequence: 3 givenname: Michael P surname: Lisanti fullname: Lisanti, Michael P – sequence: 4 givenname: Franco surname: Capozza fullname: Capozza, Franco |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23390568$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLxDAcxIOsuA_9CpKjl0KSNml7lMUXLHjRc8nj3xptkpqkK_vtLajgaQbmxwzMFq188HCGNrStyqKhFV3982u0TemdEMFbwS7QmpVlS7hoNui4l0eKrX-zyuaEFXg7eJw-rMd5diFiA0cYw-TA5wXDEuevUKQsB8BaRm19GMBDsgm7YGDE6oTTPE0RUrJ-wDBZA9HJEU8xjLaHKLMN_hKd93JMcPWrO_R6f_eyfywOzw9P-9tDMTEhcqFaTk3NakJLonsFZUOgrGXNeC0EMbyHJTBMs4oYIhajCAXJSa-1adqqZTt089O7rH_OkHLnbNIwjtJDmFNHWcMrQQXlC3r9i87KgemmaJ2Mp-7vK_YNahRqVw |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1943-8141 |
| ExternalDocumentID | 23390568 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: T32 CA009678 |
| GroupedDBID | --- 23M 2WC 53G ADBBV AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL C1A DIK F5P GX1 HYE NPM OK1 RNS RPM TR2 7X8 OVT |
| ID | FETCH-LOGICAL-p266t-b951d7270130cfbe380e37a7257660d5fe130d2c240d06d2cb01ea50fccd89492 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 7 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000318280700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1943-8141 |
| IngestDate | Sun Nov 09 10:24:33 EST 2025 Thu Apr 03 06:59:09 EDT 2025 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Keywords | skin skin cancer two stage carcinogenesis Cav1 caveolin |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p266t-b951d7270130cfbe380e37a7257660d5fe130d2c240d06d2cb01ea50fccd89492 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23390568 |
| PQID | 1285461615 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1285461615 pubmed_primary_23390568 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-01 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of translational research |
| PublicationTitleAlternate | Am J Transl Res |
| PublicationYear | 2013 |
| References | 11912134 - Cancer Res. 2002 Mar 15;62(6):1641-7 15105299 - Carcinogenesis. 2004 Sep;25(9):1771-8 20406988 - Cancer Res. 2010 May 15;70(10):4222-32 15383654 - Physiol Rev. 2004 Oct;84(4):1341-79 9361015 - J Biol Chem. 1997 Nov 14;272(46):29337-46 15548572 - Am J Physiol Cell Physiol. 2005 Mar;288(3):C677-91 11327308 - IUBMB Life. 2000 Dec;50(6):361-4 12223531 - Pharmacol Rev. 2002 Sep;54(3):431-67 11289096 - Cancer Res. 2001 Mar 15;61(6):2361-4 9822607 - EMBO J. 1998 Nov 16;17(22):6633-48 10464309 - J Biol Chem. 1999 Sep 3;274(36):25718-25 9662443 - FEBS Lett. 1998 Jun 16;429(3):330-6 19005485 - J Invest Dermatol. 2009 Apr;129(4):927-36 17071600 - Am J Pathol. 2006 Nov;169(5):1784-801 9197827 - Arch Dermatol. 1997 Jun;133(6):735-40 20709760 - Cancer Res. 2010 Oct 1;70(19):7489-99 8176018 - J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 8567687 - J Biol Chem. 1996 Jan 26;271(4):2255-61 14681688 - Nat Rev Cancer. 2004 Jan;4(1):23-35 9654135 - FEBS Lett. 1998 May 29;428(3):205-11 17496918 - Oncogene. 2007 May 14;26(22):3227-39 15343391 - J Clin Invest. 2004 Sep;114(5):720-8 17254359 - Mol Cancer. 2007;6:10 11358800 - Cancer Res. 2001 May 15;61(10):3882-5 10521449 - J Biol Chem. 1999 Oct 22;274(43):30636-43 15689413 - Am J Physiol Cell Physiol. 2005 Jun;288(6):C1317-31 12366416 - Br J Dermatol. 2002 Oct;147(4):701-9 12631721 - Mol Biol Cell. 2003 Mar;14(3):1027-42 12759258 - Am J Pathol. 2003 Jun;162(6):2029-39 15905207 - Carcinogenesis. 2005 Oct;26(10):1657-67 11283610 - Nat Cell Biol. 2001 Apr;3(4):368-75 11274625 - N Engl J Med. 2001 Mar 29;344(13):975-83 11457855 - J Biol Chem. 2001 Oct 12;276(41):38121-38 12368209 - Am J Pathol. 2002 Oct;161(4):1357-69 10582690 - Cancer Res. 1999 Nov 15;59(22):5719-23 9801158 - FEBS Lett. 1998 Oct 9;436(3):403-10 13263332 - J Biophys Biochem Cytol. 1955 Sep 25;1(5):445-58 17938246 - J Cell Biol. 2007 Oct 22;179(2):341-56 12388077 - Am J Physiol Cell Physiol. 2003 Feb;284(2):C457-74 16908356 - J Am Acad Dermatol. 2006 Sep;55(3):490-500 8662667 - J Biol Chem. 1996 May 17;271(20):11930-5 15681519 - J Clin Oncol. 2005 Feb 1;23(4):759-65 8550621 - J Biol Chem. 1996 Jan 5;271(1):568-73 8242866 - Carcinogenesis. 1993 Nov;14(11):2353-8 8621645 - J Biol Chem. 1996 Apr 19;271(16):9690-7 14731661 - Trends Cell Biol. 1994 Jul;4(7):231-5 10464308 - J Biol Chem. 1999 Sep 3;274(36):25708-17 20231499 - Arch Dermatol. 2010 Mar;146(3):283-7 19713956 - Nat Protoc. 2009;4(9):1350-62 7882334 - Cancer Res. 1995 Mar 15;55(6):1347-50 10218480 - FEBS Lett. 1999 Apr 9;448(2-3):221-30 22502704 - Asian Pac J Cancer Prev. 2012;13(1):371-5 15502164 - Methods Mol Biol. 2005;289:3-14 18451788 - Nat Protoc. 2008;3(5):799-810 21372320 - Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83 |
| References_xml | – reference: 11327308 - IUBMB Life. 2000 Dec;50(6):361-4 – reference: 8550621 - J Biol Chem. 1996 Jan 5;271(1):568-73 – reference: 17496918 - Oncogene. 2007 May 14;26(22):3227-39 – reference: 20231499 - Arch Dermatol. 2010 Mar;146(3):283-7 – reference: 14731661 - Trends Cell Biol. 1994 Jul;4(7):231-5 – reference: 12368209 - Am J Pathol. 2002 Oct;161(4):1357-69 – reference: 19005485 - J Invest Dermatol. 2009 Apr;129(4):927-36 – reference: 15383654 - Physiol Rev. 2004 Oct;84(4):1341-79 – reference: 11283610 - Nat Cell Biol. 2001 Apr;3(4):368-75 – reference: 8621645 - J Biol Chem. 1996 Apr 19;271(16):9690-7 – reference: 8662667 - J Biol Chem. 1996 May 17;271(20):11930-5 – reference: 15681519 - J Clin Oncol. 2005 Feb 1;23(4):759-65 – reference: 9361015 - J Biol Chem. 1997 Nov 14;272(46):29337-46 – reference: 16908356 - J Am Acad Dermatol. 2006 Sep;55(3):490-500 – reference: 19713956 - Nat Protoc. 2009;4(9):1350-62 – reference: 12388077 - Am J Physiol Cell Physiol. 2003 Feb;284(2):C457-74 – reference: 21372320 - Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83 – reference: 9801158 - FEBS Lett. 1998 Oct 9;436(3):403-10 – reference: 8242866 - Carcinogenesis. 1993 Nov;14(11):2353-8 – reference: 11912134 - Cancer Res. 2002 Mar 15;62(6):1641-7 – reference: 11457855 - J Biol Chem. 2001 Oct 12;276(41):38121-38 – reference: 12223531 - Pharmacol Rev. 2002 Sep;54(3):431-67 – reference: 9662443 - FEBS Lett. 1998 Jun 16;429(3):330-6 – reference: 17938246 - J Cell Biol. 2007 Oct 22;179(2):341-56 – reference: 15689413 - Am J Physiol Cell Physiol. 2005 Jun;288(6):C1317-31 – reference: 13263332 - J Biophys Biochem Cytol. 1955 Sep 25;1(5):445-58 – reference: 15105299 - Carcinogenesis. 2004 Sep;25(9):1771-8 – reference: 7882334 - Cancer Res. 1995 Mar 15;55(6):1347-50 – reference: 10218480 - FEBS Lett. 1999 Apr 9;448(2-3):221-30 – reference: 20709760 - Cancer Res. 2010 Oct 1;70(19):7489-99 – reference: 17254359 - Mol Cancer. 2007;6:10 – reference: 9654135 - FEBS Lett. 1998 May 29;428(3):205-11 – reference: 10582690 - Cancer Res. 1999 Nov 15;59(22):5719-23 – reference: 12366416 - Br J Dermatol. 2002 Oct;147(4):701-9 – reference: 10464309 - J Biol Chem. 1999 Sep 3;274(36):25718-25 – reference: 18451788 - Nat Protoc. 2008;3(5):799-810 – reference: 14681688 - Nat Rev Cancer. 2004 Jan;4(1):23-35 – reference: 20406988 - Cancer Res. 2010 May 15;70(10):4222-32 – reference: 9197827 - Arch Dermatol. 1997 Jun;133(6):735-40 – reference: 17071600 - Am J Pathol. 2006 Nov;169(5):1784-801 – reference: 22502704 - Asian Pac J Cancer Prev. 2012;13(1):371-5 – reference: 9822607 - EMBO J. 1998 Nov 16;17(22):6633-48 – reference: 15548572 - Am J Physiol Cell Physiol. 2005 Mar;288(3):C677-91 – reference: 8176018 - J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 – reference: 12631721 - Mol Biol Cell. 2003 Mar;14(3):1027-42 – reference: 10464308 - J Biol Chem. 1999 Sep 3;274(36):25708-17 – reference: 15905207 - Carcinogenesis. 2005 Oct;26(10):1657-67 – reference: 15343391 - J Clin Invest. 2004 Sep;114(5):720-8 – reference: 11358800 - Cancer Res. 2001 May 15;61(10):3882-5 – reference: 11289096 - Cancer Res. 2001 Mar 15;61(6):2361-4 – reference: 12759258 - Am J Pathol. 2003 Jun;162(6):2029-39 – reference: 8567687 - J Biol Chem. 1996 Jan 26;271(4):2255-61 – reference: 10521449 - J Biol Chem. 1999 Oct 22;274(43):30636-43 – reference: 15502164 - Methods Mol Biol. 2005;289:3-14 – reference: 11274625 - N Engl J Med. 2001 Mar 29;344(13):975-83 |
| SSID | ssj0065962 |
| Score | 1.9844854 |
| Snippet | Caveolin-1 (Cav1) is the main protein component of the membrane lipid rafts caveolae. Cav1 serves as a scaffolding protein that compartmentalizes a multitude... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 80 |
| Title | Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23390568 https://www.proquest.com/docview/1285461615 |
| Volume | 5 |
| WOSCitedRecordID | wos000318280700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvAa3DybnESKxYMtPaj0VnazkxrUTWzSiv_emSS1J0HwEgJJIOzOznw73-x8jF3ZkdQYVaSlIRKWBzKyQvBxXQnXdxVaSFA10n5-6AwG4WgUDZuEW9GUVS58YuWodRZTjvzapqN-AeGTm_zDItUoYlcbCY1V1nIRypBVd0Y_LEJAyjIVq-y5lOqyf0eRVTTpbf_3P3bYVoMj-W098btsBcwe2-g3TPk-m3fl3OapeUlVWhZcgUknhhevqeHl7D2bcr2sFsLXuOTlZ2YhVJwAj0lfyGQTcoNpwSuxHK6-eDHL67JZM-FAyrLo1N94Tro_CdSWdMCeeneP3Xur0ViwcgzNpaUQYWnEMERgxokCNxTgdmSH9iGB0H4C-EA7MQZ-LQK8UcIG6YskjnUYeZFzyNZMZuCYcQSLoQNSgKeo5Uwc6UQq4eMW25ahlrrNLhcjOkYbJmJCGshmxXg5pm12VE_LOK-bbYwd140QpIUnf_j6lG06lVoFZUjOWCvBFQznbD2el2kxvaiMA6-DYf8bbuDJDQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cav1+inhibits+benign+skin+tumor+development+in+a+two-stage+carcinogenesis+model+by+suppressing+epidermal+proliferation&rft.jtitle=American+journal+of+translational+research&rft.au=Trimmer%2C+Casey&rft.au=Sotgia%2C+Federica&rft.au=Lisanti%2C+Michael+P&rft.au=Capozza%2C+Franco&rft.date=2013-01-01&rft.issn=1943-8141&rft.eissn=1943-8141&rft.volume=5&rft.issue=1&rft.spage=80&rft_id=info%3Apmid%2F23390568&rft_id=info%3Apmid%2F23390568&rft.externalDocID=23390568 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1943-8141&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1943-8141&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1943-8141&client=summon |